SynthesisFrontiers in oncology2025
The association between gastric cancer and sarcopenia: a scoping review.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative contributions of visceral adiposity and muscle-related parameters to postoperative complications after gastrectomy: a domain-based analysis.BMC cancer · 2026Article
- Association of a standardized nursing protocol with postoperative complications following open radical gastrectomy: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To explore the relationship between gastric cancer and sarcopenia and review the underlying mechanisms. Method: A systematic search was conducted across the Web of Science, PubMed, Cochrane, CNKI, Wanfang, and VIP databases following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Literature describing the relationship between gastric cancer and sarcopenia was included in this study, with methodological quality assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. Results: Among the 1,518 identified publications, 33 cohort studies involving 10,679 participants were ultimately included. The results revealed a sarcopenia prevalence ranging from 6.8% to 72.22% in gastric cancer patients. Most studies indicated that reduced muscle mass-potentially attributable to fat infiltration, immunosuppression, cachexia-associated metabolic disturbances, and protein reserve depletion-serves as an independent predictor of postoperative complications, overall survival, and disease-free survival in gastric cancer patients. However, due to heterogeneity in assessment criteria and measurement tools, only two studies demonstrated that sarcopenia did not significantly impact survival or prognosis in this population. Conclusion: Postoperative sarcopenia exhibits a high prevalence after gastric cancer surgery and is a significant predictor of adverse clinical outcomes. This underscores the importance of prioritizing muscle mass preservation in postoperative management and integrating its assessment into preoperative risk stratification. However, the current body of evidence is limited by inconsistent diagnostic criteria and a lack of mechanistic studies. Future research should focus on establishing standardized diagnostic frameworks through multidisciplinary collaboration and developing targeted interventions to improve patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.